Highly Active Antiretroviral Therapies Are Effective against HIV-1 Cell-to-Cell Transmission

PLoS Pathogens

Volumn 10, Issue 2, 2014, Pages

  Agosto, Luis M ^a   Zhong, Peng ^a   Munro, James ^a   Mothes, Walther ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLERIXAFOR; PROTEINASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CD4+ T LYMPHOCYTE; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; POLYMERASE CHAIN REACTION; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84897699718     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003982     Document Type: Article

References (65)

1. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191.
2. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. The New England journal of medicine 337: 734-739.
3. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, et al. (2006) The survival benefits of AIDS treatment in the United States. The Journal of infectious diseases 194: 11-19.
4. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, et al. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. The New England journal of medicine 337: 725-733.
5. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009) The challenge of finding a cure for HIV infection. Science 323: 1304-1307.
6. Sattentau Q, (2008) Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 6: 815-826.
7. Zhong P, Agosto LM, Munro JB, Mothes W, (2013) Cell-to-cell transmission of viruses. Current opinion in virology 3: 44-50.
8. Sattentau QJ, (2011) The direct passage of animal viruses between cells. Current opinion in virology 1: 396-402.
9. Dimitrov DS, Willey RL, Sato H, Chang LJ, Blumenthal R, et al. (1993) Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 67: 2182-2190.
10. Carr JM, Hocking H, Li P, Burrell CJ, (1999) Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology 265: 319-329.
11. Chen P, Hubner W, Spinelli MA, Chen BK, (2007) Predominant Mode of Human Immunodeficiency Virus Transfer between T Cells Is Mediated by Sustained Env-Dependent Neutralization-Resistant Virological Synapses. J Virol 81: 12582-12595.
12. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O, (2007) Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol 81: 1000-1012.
13. Hubner W, McNerney GP, Chen P, Dale BM, Gordon RE, et al. (2009) Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science 323: 1743-1747.
14. Jin J, Sherer NM, Heidecker G, Derse D, Mothes W, (2009) Assembly of the murine leukemia virus is directed towards sites of cell-cell contact. PLoS Biol 7: e1000163.
15. Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, et al. (2003) Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 299: 1713-1716.
16. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, et al. (2003) Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 300: 1295-1297.
17. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ, (2004) HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 199: 283-293.
18. Russell RA, Martin N, Mitar I, Jones E, Sattentau QJ, (2013) Multiple proviral integration events after virological synapse-mediated HIV-1 spread. Virology 443: 143-149.
19. Del Portillo A, Tripodi J, Najfeld V, Wodarz D, Levy DN, et al. (2011) Multiploid inheritance of HIV-1 during cell-to-cell infection. Journal of virology 85: 7169-7176.
20. Zhong P, Agosto LM, Ilinskaya A, Dorjbal B, Truong R, et al. (2013) Cell-to-Cell Transmission Can Overcome Multiple Donor and Target Cell Barriers Imposed on Cell-Free HIV. PloS one 8: e53138.
21. Gratton S, Cheynier R, Dumaurier MJ, Oksenhendler E, Wain-Hobson S, (2000) Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proceedings of the National Academy of Sciences of the United States of America 97: 14566-14571.
22. Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, et al. (2002) Recombination: Multiply infected spleen cells in HIV patients. Nature 418: 144.
23. Doitsh G, Cavrois M, Lassen KG, Zepeda O, Yang Z, et al. (2010) Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 143: 789-801.
24. Cooper A, Garcia M, Petrovas C, Yamamoto T, Koup RA, et al. (2013) HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature 498: 376-379.
25. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, et al. (2013) Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature In Press.
26. Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh G, et al. (2013) IFI16 DNA Sensor Is Required for Death of Lymphoid CD4 T Cells Abortively Infected with HIV. Science In Press.
27. Josefsson L, Palmer S, Faria NR, Lemey P, Casazza J, et al. (2013) Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule. PLoS pathogens 9: e1003432.
28. Josefsson L, King MS, Makitalo B, Brannstrom J, Shao W, et al. (2011) Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proceedings of the National Academy of Sciences of the United States of America 108: 11199-11204.
29. Richardson MW, Carroll RG, Stremlau M, Korokhov N, Humeau LM, et al. (2008) Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. J Virol 82: 11117-11128.
30. Abela IA, Berlinger L, Schanz M, Reynell L, Gunthard HF, et al. (2012) Cell-Cell Transmission Enables HIV-1 to Evade Inhibition by Potent CD4bs Directed Antibodies. PLoS pathogens 8: e1002634.
31. Jolly C, Booth NJ, Neil SJ, (2010) Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol 84: 12185-12199.
32. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, et al. (2011) Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477: 95-98.
33. Duncan CJ, Russell RA, Sattentau QJ, (2013) High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy. AIDS 27: 2201-2206.
34. Permanyer M, Ballana E, Ruiz A, Badia R, Riveira-Munoz E, et al. (2012) Antiretroviral Agents Effectively Block HIV Replication after Cell-to-Cell Transfer. Journal of virology 86: 8773-8780.
35. Mazurov D, Ilinskaya A, Heidecker G, Lloyd P, Derse D, (2010) Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors. PLoS pathogens 6: e1000788.
36. Titanji BK, Aasa-Chapman M, Pillay D, Jolly C, (2013) Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells. Retrovirology 10: 161.
37. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, et al. (2012) Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. Journal of virology 86: 2715-2728.
38. Sampah ME, Shen L, Jilek BL, Siliciano RF, (2011) Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proceedings of the National Academy of Sciences of the United States of America 108: 7613-7618.
39. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, et al. (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nature medicine 14: 762-766.
40. Rooke R, Tremblay M, Soudeyns H, DeStephano L, Yao XJ, et al. (1989) Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS 3: 411-415.
41. Larder BA, Darby G, Richman DD, (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731-1734.
42. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2013). http://aidsinfonihgov/contentfiles/lvguidelines/AdultandAdolescentGLpdf: p. F1-20.
43. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA, (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Molecular cell 4: 35-43.
44. Boyer PL, Sarafianos SG, Arnold E, Hughes SH, (2001) Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. Journal of virology 75: 4832-4842.
45. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA, (1998) Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37: 15908-15917.
46. Feng JY, Ly JK, Myrick F, Goodman D, White KL, et al. (2009) The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology 6: 44.
47. Gotte M, Arion D, Parniak MA, Wainberg MA, (2000) The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. Journal of virology 74: 3579-3585.
48. Boyer PL, Sarafianos SG, Arnold E, Hughes SH, (2002) The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. Journal of virology 76: 3248-3256.
49. Tisdale M, Kemp SD, Parry NR, Larder BA, (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences of the United States of America 90: 5653-5656.
50. Schinazi RF, Lloyd RM Jr, Nguyen MH, Cannon DL, McMillan A, et al. (1993) Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial agents and chemotherapy 37: 875-881.
51. Eisele E, Siliciano RF, (2012) Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37: 377-388.
52. Murooka TT, Deruaz M, Marangoni F, Vrbanac VD, Seung E, et al. (2012) HIV-infected T cells are migratory vehicles for viral dissemination. Nature 490: 283-287.
53. Sewald X, Gonzalez DG, Haberman AM, Mothes W, (2012) In vivo imaging of virological synapses. Nature communications 3: 1320.
54. Clavel F, Hance AJ, (2004) HIV drug resistance. The New England journal of medicine 350: 1023-1035.
55. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, et al. (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277: 112-116.
56. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, et al. (2012) A quantitative basis for antiretroviral therapy for HIV-1 infection. Nature medicine 18: 446-451.
57. Rosenbloom DI, Hill AL, Rabi SA, Siliciano RF, Nowak MA, (2012) Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nature medicine 18: 1378-1385.
58. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, et al. (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. Journal of virology 59: 284-291.
59. Nowicka-Sans B, Gong YF, McAuliffe B, Dicker I, Ho HT, et al. (2012) In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrobial agents and chemotherapy 56: 3498-3507.
60. Hanna GJ, Lalezari J, Hellinger JA, Wohl DA, Nettles R, et al. (2011) Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. Antimicrobial agents and chemotherapy 55: 722-728.
61. Lin PF, Blair W, Wang T, Spicer T, Guo Q, et al. (2003) A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proceedings of the National Academy of Sciences of the United States of America 100: 11013-11018.
62. O'Doherty U, Swiggard WJ, Malim MH, (2000) Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 74: 10074-10080.
63. Pelchen-Matthews A, Parsons IJ, Marsh M, (1993) Phorbol ester-induced downregulation of CD4 is a multistep process involving dissociation from p56lck, increased association with clathrin-coated pits, and altered endosomal sorting. The Journal of experimental medicine 178: 1209-1222.
64. Agosto LM, Yu JJ, Dai J, Kaletsky R, Monie D, et al. (2007) HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology 368: 60-72.
65. Nettles RE, Schurmann D, Zhu L, Stonier M, Huang SP, et al. (2012) Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. The Journal of infectious diseases 206: 1002-1011.